Curity Pharma, a Greece-based cannabis growing company, has officially received its operating license from the Ministries of Development, Health, and Rural Development. This approval allows the immediate start of full operations at its vertically integrated medical cannabis facility.
Curity Pharma's new Good Manufacturing Practice (GMP) compliant hybrid greenhouse is fully equipped with cutting-edge technology, in accordance with the highest European standards of quality and safety. "We decided early on to go for a hybrid greenhouse as opposed to an indoor facility, to try and combine the stability and controllability of conditions that an indoor facility provides while also taking advantage of the optimal climate conditions that Greece offers for growing cannabis and thus reducing operating expenses and the resulting carbon footprint these entail," explains Leonidas Garyfallos, COO of Curity. "In a nutshell, a hybrid greenhouse provides for increased levels of control at a reasonable cost."
Curity Pharma has invested in building a specialized team of scientists, technicians, researchers, and pharmaceutical industry professionals to meet the growing demands of the European market and be able to grow high quality medical cannabis despite the usual challenge that every horti grower faces. "Greece's climate is as ideal as it gets for growing cannabis, with plenty of natural sunlight to support healthy plant growth," Leonidas continues. "Having said that, the climate comes with its challenges, warm summers, intense UV exposure, and seasonal humidity shifts. That's where our hybrid, high-tech greenhouse helps to create the "just right" zone for growing. By combining the benefits of an indoor cultivation and a greenhouse with smart technology, we create the perfect balance, controlling temperature, humidity, and light to keep our plants healthy. With automated irrigation, energy-efficient climate control, and sustainable growing methods, we grow efficiently and consistently, high-quality medical cannabis."
Manos Chatiras, co-founder, chairman, and CEO of Curity Pharma states: "This license marks the beginning of a new chapter for Curity Pharma and the medical cannabis industry. Greece is becoming an important player in the European medical cannabis sector, driving solutions based on science and advanced technology. Our vision for developing and producing innovative therapies is now coming to life, and we are ready to implement our strategy to offer the best therapeutic solutions to Greek patients, while also executing our export plan to establish Greek medical cannabis as a reference point across Europe."
And Europe is indeed the main market for Curity, as also Leonidas points out, but there's more to come . "We will be active in the European market including, of course, our home market, Greece. Having said that, we are also exploring opportunities across all the legal medical cannabis markets and outside of Europe such as Australia, Israel, etc."
With production now ramping up, it's only a matter of time before the first medical cannabis products get out of the Curity cultivation facility. "We expect to have our first harvest in June and have products ready for the market in Q4 2025 to Q1 2026," concludes Leonidas.
For more information:
Curity Pharma
P: +30 210 6390267
F: +30 210 6199565
E: info@curitypharma.com
curitypharma.com